Introduction.
Introduction.At Shift, we’re targeting the underlying cause of age driven diseases, the aging cell.
With age, health costs rise an order of magnitude, peaking at £10k/yr (UK, 2020-21) due to an increased prevalence of age-driven diseases. Shift aims to safely reverse age-driven diseases at their source, the aging cell, to harness the unrivalled resilience and repair capacity of younger cells, tissues and organs.
Platform.
Best-in-class target discovery platform for cellular rejuvenation.
AC4.
Shift Bioscience has combined a novel aging clock (AC4) and virtual cell model to remove the primary bottleneck for discovery of cellular aging and rejuvenation targets, experimental throughput. This enables the discovery of hundreds of novel targets including those linked to disease states.
Shift’s platform is linking cellular aging to disease states.
Product.
An anti-fibrotic siRNA therapeutic for cell rejuvenation.
SB101 knockdown reverses epigenetic aging clocks in multiple cell types and is part of a systemic, genetically validated fibrosis pathway.
siRNA knockdown of SB101 provides a straightforward regulatory path to clinical proof of concept, with first in class opportunities in liver fibrosis and expansion potential to secondary fibrosis (lung, heart).
SB101.
Company.
Shift is Cambridge (UK) based with field leading Longevity founders and management.
Key personnel in Boston (US) provide a foothold for liver siRNA development and corporate leadership. Shift has built a comprehensive IP package for its fibrosis and cell rejuvenation programs (LOE 2046) with the opportunity for follow-on IP in siRNA delivery technology. Shift is seeking strategic partnerships that accelerate the first medicines capable of prolonging healthspan and lifespan.
Latest News.
Latest News.Shift Bioscience publishes improved metric calibration framework for robust genetic perturbation modeling using AI Virtual Cells